Reliant Investment Management LLC increased its position in Celgene Corporation (NASDAQ:CELG) by 0.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,985 shares of the biopharmaceutical company’s stock after buying an additional 180 shares during the quarter. Celgene Corporation accounts for approximately 2.8% of Reliant Investment Management LLC’s holdings, making the stock its 13th biggest holding. Reliant Investment Management LLC’s holdings in Celgene Corporation were worth $3,634,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. State Street Corp increased its position in Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares during the period. Jennison Associates LLC increased its position in Celgene Corporation by 1.2% during the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares during the period. Pioneer Investment Management Inc. increased its position in Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after purchasing an additional 710,584 shares during the period. Clearbridge Investments LLC increased its position in Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares during the period. Finally, Legal & General Group Plc increased its position in Celgene Corporation by 4.6% during the 2nd quarter. Legal & General Group Plc now owns 3,751,507 shares of the biopharmaceutical company’s stock valued at $487,210,000 after purchasing an additional 163,884 shares during the period. 78.92% of the stock is currently owned by institutional investors.

Shares of Celgene Corporation (CELG) opened at $102.34 on Friday. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a market cap of $80,668.49, a PE ratio of 16.01, a PEG ratio of 0.79 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.58 EPS. sell-side analysts expect that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/reliant-investment-management-llc-has-3-63-million-position-in-celgene-corporation-celg/1694867.html.

A number of research analysts have issued reports on the stock. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Wednesday, August 16th. BMO Capital Markets reduced their price objective on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Tuesday, September 26th. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $139.64.

In related news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the sale, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,286,027.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock valued at $2,843,956 over the last three months. 0.95% of the stock is currently owned by insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.